Menu Search
Equities

Azenta Inc

BA3:DUS

Azenta Inc

Actions
  • Price (EUR)41.80
  • Today's Change-0.20 / -0.48%
  • Shares traded12.00
  • 1 Year change-5.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 11:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company’s segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

  • Revenue in USD (TTM)658.62m
  • Net income in USD-156.38m
  • Incorporated1994
  • Employees3.30k
  • Location
    Azenta Inc200 Summit Drive, 6Th FloorBURLINGTON 01803United StatesUSA
  • Phone+1 (978) 262-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.azenta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.